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Background. Dementia was aﬀecting 855.000 patients in France in 2007. Lanmeur’s rural hospital population was representative
of the French nursing home’s population. The followup was assumed by local GPs, which is also usual care in France for nursing
homes. The study looked at clinical and paraclinical data transmitted at the institutionalization time of patients suﬀering from
dementia. Aim. showing that admission letters did allow establishing a diagnosis of dementia for the GPs. Method. we included all
patients with dementia at the time of institutionalization between July 2000 and July 2007. We searched in the admission letters for
25 criteria extracted from the French guidelines for dementia and Alzheimer disease diagnosis (multiple cross-sectional analysis
per year). Results. 293 patients were included. The median number of diagnostic criteria present in the letters of admission is 1
(ﬁrst quartile: zero, third quartile: 4, and maximum: 12). Conclusions. the data in admission letters did not allow the diagnosis of
dementia according to theFrench guidelines. We know that dementia is underchecked and undertreated in France according to the
same guidelines. What consequences did this lack of basic data give on motivation for treatment and recurrent diagnosis process
for GPs? This has to be evaluated.
1.Introduction
Dementia was aﬀecting 855.000 patients in France in
2007 [1]. 40% of them were institutionalized [2]. ANAES
(Agence nationale d’Accr´ editation et d’Evaluation en Sant´ e:
the National Agency of Accreditation and Evaluation in
Health) guidelines since February 2000 [3], according to
NINCDS-ADRDA (the National Institute of Neurological
and Communicative Disorders and Stroke—Alzheimer’s
Disease and Related Disorders Association) had 25 criteria
for positive and etiological diagnose of dementia. In France,
geriatrist, psychiatrist, or neurologist did have to initiate spe-
ciﬁc treatment. Then General Practitioners (GPs) assumed
followup. A specialised advice was strongly recommended
in primary phase of diagnosis to have a ﬁrst extensive
neuropsychiatric examination. Despite large indications [4]
for geriatrists, only-one third [5] of patients had speciﬁc
dementia treatment in France. There is a gap between those
large indications and the number of speciﬁc treatments.
Could this gap come from GPs practice and on which
diagnosis determinant could GPs base their practice and the
medical decision to treat?
According to Mulrow’s medical decision model theory
[6],medicaldecisionisbasedonatripod:Scienceandpatient
objective data, relation and communication between patient
and GPs, and constraints of the health system. If we look at
the decision of prescribing or not an antidementia drug, the
parameters came from those three orders. In the objective
data,wefounddiﬀerenttypesofinterrogations:isthepatient
suﬀering from Alzheimer’s disease? What do we know about
antidementia drugs (indications, contraindication, eﬀective-
ness, adverse drug reactions, and alternative treatments...)?2 International Journal of Family Medicine
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Figure 1: Mulrow’s model.
In the relation data: patient’s and doctor’s beliefs, values,
and professionalism. Among the constraints, cost, refund,
political health decision (Alzheimer plan in France which
push GPs to prescribe drugs) are aﬀecting decision (see
Figure 1).
For patients objective data French GPs needed clinical
and paraclinical data coming from a specialized team. All
those data were cost and time eﬀective. For all those reasons,
good transmission of medical data was important. We did
know that generally GPs preferred data coming from the
hospitalisation reports for their ﬁrst input in medical records
and that this attitude is emphasized by the French medical
council [7].So,thegoalofourstudywastoshowthatclinical
and paraclinical data in the admission letters were suﬃcient
enough to assess the diagnosis of dementia.
This was an important matter because most of those
patients were disabled and needed medical transport for any
further specialized examination. For any of those examina-
tions, GPs were always shared between assessing a diagnosis
that could change therapy and constraint (comfort) for the
patient. All this has to be done in order to be both time and
cost eﬀective for a rural hospital (which, in France, is mostly
a nursing home) and ethical and useful for the patients.
2. Method
2.1. Population. The studied population was living in Lan-
meur’s rural hospital. Care was assumed by their local GPs.
2.2. Place of Study. Lanmeur’s rural hospital is a nursing
home of 255beds. Its population has been found represen-
tative for the population of French nursing homes according
to age ratio, sex ratio, and morbidity ratio. Lanmeur has
two general hospitals in the neighbourhood (Morlaix 15km
and Lannion 25Km) and one university hospital in Brest
(70Km).
Table 1: Criteria List.
Antecedents Paraclinic exams
Alcoholism TSH
Alzheimer’s disease in family Hemoglobinemia
Illness story Natremia
Evolution Calcaemia + protidemia
Clinical exam Glycaemia
Vigilance Brain imaging
Mnestic trouble Syphilis
Depression HIV
Neurological exam B12
Scores and tests Foliates
IADL Hepatic Function (INR)
MMS Lumbar Puncture
Simple cognitive test EEG
Complex cognitive test Advice
Specialized advice
2.3. Inclusion. We did include all patients with coded Al-
zheimer disease or other dementias in ICM 10 as antecedent
or diagnosis.
2.4. Exclusion. We did exclude patients with wrong coding
(Alzheimer’s plus other dementia in the same record),
patients with false coding (paper charts with diﬀerent
diagnosis or antecedent than in computerized record), and
patients with lost admission letter (letter was considered lost
if it was mentioned in the medical records and not found,
otherwise we supposed that we had no admission letter).
Inclusion or exclusion was made from database records.
Diagnosis criteria were all extracted directly and only from
the original letter.
2.5. Search Criteria. The 25 criteria were extracted from
the French national guidelines for Alzheimer’s disease and
dementia published by the ANAES in 2000 [3]. We did
extract their attendance not their value (We did record all
mentioned criteria in the entry mail neither positive or
negative value) (see Table 1).
Criteria recording was done as follows for each criterio:
Alcoholism (if found as alcoholism, alcohol, alcohol
troubles),
Familial antecedent of dementia (if mentioned),
Vigilance state (if mentioned),
IADL score (if quoted),
MMS score (if quoted),
Description of biological results: we did accept a sin-
gle qualiﬁcation for glycaemia (normal or not) and
for serology (positive or negative) or the numbers,
Brain imaging considered done if the result was
written (for RMN or Scan) or at least mentioned.
Multicriteria as: memory impairment, cognitive tests.
Cognitive testing was separated in two types: simpleInternational Journal of Family Medicine 3
Table 2: Included and excluded admission letters.
Included and excluded admission letters
Found letter Unfound letter Total
Correct ICM 10 coding 293 20 313
Wrong ICM 10 coding 44 5 49
TOTAL 337 25 362
(5 words, clock test, verbal ﬂuency, arithmetic test, and
similarity test) and complex (Grober and Buschke test,
California Verbal Learning Test, Mattis scale, and WAIS
(WechslerAdultIntelligenceScaleRevised)).Ifatleastoneof
those tests was written as performed the item was validated
as positive.
At last, a third category of criteria needed a precise deﬁ-
nition like evolution, neurological examination, depression,
and specialized examination:
Progressive evolution was quoted as present if the
mail did mention that troubles did appear in a
progressive way or if some troubles did precede a
quick alteration.
Neurological exam was quoted as present if the
notion of normality of this exam was quoted or at
least one description of one neurological sign.
Depression was quoted if one result positive or
negative of a test was written or if one treatment
of depression was found (any type of antidepressive
drugs).
Specialized advice was quoted if it was mentioned
that a geriatrist, neurologist, or psychiatrist saw the
patientorifthepatientwascomingfromsuchaward.
2.6.DataRecordingandAnalysis. Everyletterwastakenfrom
the ﬁles and manually read. Epi Data Entry ver 3.1 was
used for recording. Epi data Analysis version 1.1 (build 68)
has been used for multiple transversal analysis (on order to
describemailevolutionintime).Resultsareinabsolutevalue
and in percentiles of patients with analysed mail (293). No
signiﬁcance test was used because of lack of valid valuator.
Age and numbers of criteria in the mail are showed in
quartile.
3. Results
681 patients were in our database. 378 were suﬀering of
dementia at entry. 362 were possible to include with 30
Alzheimer’s diseases and 332 dementias without aetiology.
From those 362 patients, 69 were excluded because of
incompleteﬁles.Thismeanslostletterorpatientwithoutany
letter (average 23.5%, maximum 37.5%, and minimum 20%
per year), wrong ICM 10 coding or diﬀerent coding between
manual ﬁles and electronic record (see Table 2).
From 362 patients, only 293 letters were exploitable and
studied. Those patients mostly came from the three closest
hospitals. They were coming from geriatric, neurologic,
or internal medicine wards at almost 95% (30 diﬀerent
Table 3: Results for each recommended criteria.
Antecedents Number
(% on 293) Paraclinic exams Number
(% on 293)
Alcoholism 8.2 TSH 7.5
Alzheimer’s disease
in family 0.3 Hemoglobinemia 22.9
Illness story Natremia 13.3
Evolution 8.9 Calcaemia +
protidemia 2.0
Clinical exam Glycaemia 8.2
Vigilance 13.0 Brain imaging 24.9
Mnestic trouble 9.9 Syphilis 0.3
Depression 27.7 HIV 0.3
Neurological exam 24.2 B12 2.4
Scores and tests Foliates 2.4
IADL 0.0 Hepatic Function
(INR) 6.1
MMS 10.6 Lumbar Puncture 0.3
Simple cognitive test 2.4 EEG 4.1
Complex cognitive
test 0.0 Advice
Specialized advice 42.7
hospitalists). Medium age at entry was 83,5 years old (78,75;
88,5). Women were 206 (70,3%), and 74,5% were more than
75 years old. Six patients did arrive in 1990 or before, 11
between 1991 and 1995 to 47 in 2004, 38 in 2005, and 14
in 2006. 257 (87,71%) patients had an unidentiﬁed dementia
(see Table 3).
Personal and family antecedent were written in less than
10%. Family antecedent of Alzheimer’s disease was only
present in one case. Mnestic troubles were described in less
than 10%.
Clinical tests that could give indication for a diﬀerential
diagnosis than Alzheimer’s disease (evolution, associated
depression, and neurological clinic anomalies) were found
in, respectively, 9%, 28%, and 24%.
Scores were very lowly present; MMS was almost the
only one and was found at 11%. IADL and other specialised
tests were never seen. By biological exam (especially rec-
ommended to exclude an organic aetiology of dementia)
hemoglobinemia (23%), and natremia (13%) were the only
ones that overrun 10%. Specialised advice was present for
43%.
The median amount of criteria present per mail is only
one [0;4] on 25 recommended by ANAES. Evolution of the
median amount of criteria with time is shown in Table 4.N o
signiﬁcative diﬀerence was seen between addressing wards or
addressing practitioners.
4. Discussion
Here are the limits (strength and weaknesses) of our study.
The population was representative of the French
nursing homes population [8].4 International Journal of Family Medicine
Table 4: Evolution of found criteria from 1995 to 2006.
From 1995 to 1999
(n = 60)
2000 (n = 22) 2001 (n = 35) 2002 (n = 40) 2003 (n = 37) 2004 (n = 47) 2005 (n = 38) 2006 (n = 14)
1[ 0 .25; 4] 1 [0; 4] 1 [0; 4] 1 [0; 2] 2 [1; 4] 1 [0; 3] 3 [1; 5] 5 [1.5; 6.75]
Other ways of communication like phone call and
electronic mail were not analyzed because, in France,
they are not part of the medical records. In French
real life, they were not used for medical communica-
tion and they were not liked at all by French GPs [7].
So it should not change our results.
We had only one reviewer: it was possible to miss
some data.
With those limits our study shows some surprises.
Diagnoses criteria of dementia written in the patient’s
admission letter in a French nursing home were very low.
Half of those letters had only one or zero criteria on the
25 recommended by the French authorities. Even if there
is a light amelioration in 2005 and 2006 (Table 4), criteria
descriptionstaysverylittletilltheendofthestudyandwould
not allow GPs conﬁdence in diagnosis. Most of the patients
were coming from the same wards for initial diagnosis, and
we could incriminate those wards practice. But all of them
do represent 30 diﬀerent hospitalists, and our results were
reproducible from one to another. It was known for long
that despite the fact that the medical job should be done,
communication from hospitals to GPs is not so good [9].
A specialised advice was done in less than half of the
cases. This was a surprise because, in France, specialised
advice is supposed to be compulsory to give antidementia
speciﬁc drug therapy. It could be one explanation of the
poor rate of drug therapy for dementia in our country.
As GPs should not do the initiation of speciﬁc treatment,
they have to ask for another advice in 57% of patients
to do this treatment. This is an additional cost for the
health system, and as it is already known that GPs are
criticizing antidementia drugs eﬀects, will they do again all
the diagnosis process?
Another surprise was that we had only 8% of alcoholism
reported. The French population is a high alcohol user pop-
ulation and men’s mortality in Brittany (our place of study)
directly linked to alcoholism is very high (126.2/100000
against 70.4/100000 for all France) [10, 11]. Is this aetiology
of dementia checked? And if not is the initial diagnosis in
secondary care correctly done? This stays as a question.
A familial antecedent of Alzheimer’s disease is an impor-
tant risk factor (OR = 3,5, IC ` a 95%: 2,6–4,6) [12]b u ti so n l y
found in 1 mail on 293...is this checked too?
Sudden evolution and neurological clinical signs are for
the diagnosis if Alzheimer’s disease for NINCDS-ADRDA.
But this is described in 9% for evolution and 24% for
neurological exam. This is may be one explanation of the
poor quantity of Alzheimer’s disease in our study (12.29%)
against 80% in the PAQUID cohort [2]. Dartigues et al. [13]
showedin2001that52%ofpatientswithaspeciﬁctreatment
of Alzheimer’s disease did had a complete initial checkup
according to ANAES recommendations for clinical scores,
paraclinic exams, and specialised advice. Our population is
not the same with a maximum of 18% of patients under
speciﬁc therapy. This gap could come from two causes:
original etiological checkup are not so well done than in the
PAQUID study or they are not transmitted from hospitalists.
For the ﬁrst cause it could be because recommendations
are not followed. Doctors have other criteria, do not do the
complete checkups or only in selectionned populations (e.g.,
of tip-top wards doing research as their main activity like
in the PAQUID study and not only caring for people like in
nursing homes). For the second one, it could be, simply, that
communication between health professionals is low about
dementia in France as it is low for every diagnosis between
secondary and primary care [9, 14].
One last question is the impact of those incomplete
letters on GPs motivation to check and treat dementia and to
assume the followup of dementia patients. Mulrow’s model
of clinical decision [6] does insist on uncertainty as a main
factor of choice for medical decision. Our admission letters
with very few criteria do not help GPs with uncertainty.
How does this play on dementia diagnosis and treatment
in primary care in France? The literature results show only
one thing: it is done for one-third of the patients (5) one
explanation, between others, could come from our results
enlarging uncertainty for GPs decision.
5. Conclusion
Despite a light amelioration since 2000 (latest publication
of ANAES recommendations for followup of dementia), no
complete diagnosis checkup for dementia was transmitted
from secondary care to GPs in France. When it did exist
(23.5% of lost or missing letters), the admission letters did
not give evidence for the diagnosis of dementia. Diﬀerent
hypothesis could be discussed with our results: initial check-
ups done by hospitalist are incomplete; recommended cri-
teria do not match with hospitalist’s practice; poor medical
attitudeisgiven(hereinsecondarycare)tovulnerablegroups
of the population; communication is low from hospitalists to
GPs. In addition, GPs management could be criticised after
being put in an awkward situation by referring colleagues.
Anyway, from the patient’s point of view, GPs stayed in
uncertainty in front of this diagnosis without clear evidence
of it. How does this play on their motivation to treat or not
with speciﬁc drugs? How does this play on new checkups
done at high and redundant cost for aged and disabled
patients? We should go on this topic with two studies: one
on GP’s motivation using Mulrow’s decision model with
a representative GP’s sample is to answer the following
questions: will you keep an antidemential treatment (with
the already known critics about those treatments clinicalInternational Journal of Family Medicine 5
eﬃciency) if you have or not adverse eﬀects while having no
evidence of the trustfulness of the diagnosis? The other one
on discordance between diagnosis in secondary and primary
care on a representative samples of patients with dementia
(according to secondary care previous diagnosis) with a new
checkup done in primary care and following the French
recommendations.
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